Jpmorgan Chase & CO Relmada Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 158 shares of RLMD stock, worth $319. This represents 0.0% of its overall portfolio holdings.

Number of Shares
158
Previous 37,700 99.58%
Holding current value
$319
Previous $19,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$0.26 - $0.47 $9,760 - $17,644
-37,542 Reduced 99.58%
158 $0
Q4 2024

Feb 12, 2025
SELL
$0.35 - $3.65 $97,075 - $1.01 Million
-277,359 Reduced 88.03%
37,700 $19,000
Q3 2024

Dec 26, 2024
SELL
$2.3 - $4.36 $86,381 - $163,748
-37,557 Reduced 10.65%
315,059 $1.02 Million
Q3 2024

Nov 08, 2024
SELL
$2.3 - $4.36 $86,381 - $163,748
-37,557 Reduced 10.65%
315,059 $1.02 Million
Q2 2024

Dec 26, 2024
BUY
$2.93 - $4.94 $110,042 - $185,531
37,557 Added 11.92%
352,616 $1.06 Million
Q2 2024

Aug 12, 2024
BUY
$2.93 - $4.94 $517,549 - $872,591
176,638 Added 100.38%
352,616 $1.06 Million
Q1 2024

Dec 26, 2024
SELL
$3.1 - $6.8 $431,151 - $945,750
-139,081 Reduced 44.14%
175,978 $818,000
Q1 2024

May 10, 2024
BUY
$3.1 - $6.8 $487,264 - $1.07 Million
157,182 Added 836.25%
175,978 $818,000
Q4 2023

Dec 26, 2024
SELL
$2.45 - $4.22 $725,844 - $1.25 Million
-296,263 Reduced 94.03%
18,796 $77,000
Q4 2023

Feb 12, 2024
BUY
$2.45 - $4.22 $43,945 - $75,694
17,937 Added 2088.13%
18,796 $77,000
Q2 2023

Aug 11, 2023
SELL
$2.22 - $3.54 $44,670 - $71,231
-20,122 Reduced 95.91%
859 $2,000
Q1 2023

May 18, 2023
BUY
$2.24 - $4.76 $46,997 - $99,869
20,981 New
20,981 $47,000
Q4 2022

Feb 13, 2023
SELL
$2.17 - $35.84 $3,448 - $56,949
-1,589 Reduced 9.3%
15,503 $54,000
Q3 2022

Nov 14, 2022
BUY
$18.3 - $37.02 $20,422 - $41,314
1,116 Added 6.99%
17,092 $633,000
Q2 2022

Aug 11, 2022
BUY
$16.5 - $30.34 $2,079 - $3,822
126 Added 0.79%
15,976 $304,000
Q1 2022

May 11, 2022
BUY
$16.72 - $26.99 $140,882 - $227,417
8,426 Added 113.5%
15,850 $427,000
Q4 2021

Feb 10, 2022
SELL
$16.93 - $26.82 $56,918 - $90,168
-3,362 Reduced 31.17%
7,424 $167,000
Q3 2021

Nov 12, 2021
BUY
$21.86 - $34.77 $235,781 - $375,029
10,786 New
10,786 $283,000

Others Institutions Holding RLMD

# of Institutions
55
Shares Held
5.43M
Call Options Held
0
Put Options Held
0
View Full List

About RELMADA THERAPEUTICS, INC.

RLMD Quotes by TradingView
  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $57.8M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email